Revolution Medicines’ expanded access program for daraxonrasib provides three critical developments for pancreatic cancer patients and oncologists. First, the investigational drug is now available through a compassionate use pathway for patients with advanced disease who have exhausted standard treatment options, bypassing the typical clinical trial enrollment process. Second, daraxonrasib employs precision medicine principles by targeting KRAS G12C mutations, identified in approximately 2% of pancreatic adenocarcinomas, offering genomically matched therapy for this subset of patients. Third, the company’s planned FDA submission suggests potential approval within 12-18 months, making expanded access a practical bridge to broader availability. Patients with metastatic pancreatic cancer—currently facing a three percent five-year survival rate—should discuss eligibility with their oncology team. Early access programs represent a meaningful option when standard therapies are no longer effective. Read the full article on GMJ Newsroom.
Was this article helpful?
